BCL2 and breast cancer: Regarding METTL3 in BC, data from the literature have suggested that METTL3 can promote BC progression by targeting Bcl-2, HBXIP or SOX2 [41, 45, 46] and that METTL3 could promote adriamycin resistance by accelerating pri-miRNA-221-3p maturation [47] or mediating MALAT1/E2F1/AGR2 axis [48].